Cryopreserved embryo transfer is an independent risk factor for placenta accreta

Cryopreserved embryo transfer is a strong predictor of placenta accreta among patients using in vitro fertilization and/or intracytoplasmic sperm injection. This increased risk may be associated with the thinner endometrial linings and lower estradiol levels characteristic of these cycles.

Like Comment

Authors

Daniel J. Kaser, M.D., Alexander Melamed, M.D., M.P.H., Charles L. Bormann, Ph.D., Dale E. Myers, Sc.M., Stacey A. Missmer, Sc.D., Brian W. Walsh, M.D., Catherine Racowsky, Ph.D., Daniela A. Carusi, M.D., M.Sc.

Volume 103, Issue 5, Pages 1176-1184

Abstract

Objective:

To explore the association between cryopreserved embryo transfer (CET) and risk of placenta accreta among patients utilizing in vitro fertilization (IVF) and/or intracytoplasmic sperm injection (ICSI).

Design:

Case-control study.

Setting:

Academic medical center.

Patient(s):

All patients using IVF and/or ICSI, with autologous or donor oocytes, undergoing fresh or cryopreserved transfer, who delivered a live-born fetus at ≥24 weeks of gestation at our center, from 2005 to 2011 (n = 1,571), were reviewed for placenta accreta at delivery.

Intervention(s):

Cases of accreta (n = 50) were matched by age and prior cesarean section to controls (1:3) without accreta. The association between CET and accreta was modeled using conditional logistic regression, controlling a priori for age and placenta previa. Receiver operating characteristic curves were used to determine thresholds of endometrial thickness and peak serum E2 levels related to accreta.

Main Outcome Measure(s):

Placenta accreta.

Result(s)

Univariate predictors of accreta were non-Caucasian race (odds ratio [OR] 2.85, 95% confidence interval [CI] 1.25–6.47); uterine factor infertility (OR 5.80, 95% CI 2.49–13.50); prior abdominal or laparoscopic myomectomy (OR 7.24, 95% CI 1.92–27.28); and persistent or resolved placenta previa (OR 4.25, 95% CI 1.94–9.33). In multivariate analysis, we observed a significant association between CET and accreta (adjusted OR 3.20, 95% CI 1.14–9.02), which remained when analyses were restricted to cases of accreta with morbid complications (adjusted OR 3.87, 95% CI 1.08–13.81). Endometrial thickness and peak serum E2 level were each significantly lower in CET cycles and those with accreta.

Conclusion(s):

Cryopreserved ET is a strong independent risk factor for accreta among patients using IVF and/or ICSI. A threshold endometrial thickness and a “safety window” of optimal peak E2 level are proposed for external validation.

Read the full text at: http://www.fertstert.org/article/S0015-0282(15)00068-0/fulltext


Fertility and Sterility

Editorial Office, American Society for Reproductive Medicine

Fertility and Sterility® is an international journal for obstetricians, gynecologists, reproductive endocrinologists, urologists, basic scientists and others who treat and investigate problems of infertility and human reproductive disorders. The journal publishes juried original scientific articles in clinical and laboratory research relevant to reproductive endocrinology, urology, andrology, physiology, immunology, genetics, contraception, and menopause. Fertility and Sterility® encourages and supports meaningful basic and clinical research, and facilitates and promotes excellence in professional education, in the field of reproductive medicine.

No comments yet.